Neowise Biotechnology

Suzhou, China · Founded 2020 · Privately Held (backing)

Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. Neowise Biotechnology is based in Suzhou, China and was founded in 2020. Its last reported valuation was $229 million in Oct 2025. It has raised $57.1 million.

Last reported valuation
$229.1M
Oct 2026
Priced at
—
Total raised
$57.1M
Last round
—

Who backs Neowise Biotechnology?

15 investors
InvestorType
Suzhou Oriza Holdings CorporationAsset manager
Baidu VenturesOther
Leader Venture CapitalOther
Beijing Delian Yuntong Investment Management CompanyVenture capital
Marathon Venture PartnersVenture capital
Suzhou Angel Fund of FundsOther
Suzhou Zhongxin Innovation Investment ManagementOther
Zhongxin ZibenOther
Apricot Capital (Shanghai)—
BioMap—
+ 5 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Neowise Biotechnology investors

Free account
More of Neowise Biotechnology with a free account
  • ·The complete investor list: 15 names
  • ·Watch Neowise Biotechnology: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 15 firms already write checks for companies like Neowise Biotechnology. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View